MPP Strikes Deal For Long-Acting Injectable HIV Candidate
Monthly Subcutaneous Injection Licensed From University Of Washington Could Replace Daily Pills
Executive Summary
The University of Washington has agreed to license an in-development HIV treatment to the Medicines Patent Pool, which takes the form of a monthly subcutaneous injection instead of daily oral treatment.
You may also be interested in...
Medicines Patent Pool Centers On Consolidation In Its New Three-Year Strategy
The Medicines Patent Pool’s new strategy could open the door to significant new opportunities for generic drug suppliers across low- and middle-income countries, as it explores its remit in new fields such as biologics, early-stage drug development and even – possibly – antimicrobial resistance.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1m-$10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan believes. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.
Strides CEO: US COMPETES Act Creates Quality Differentiator
The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.